Biocartis launches second liquid biopsy assay
14 December 2016 | By Niamh Louise Marriott, Digital Editor
Biocartis launched its second liquid biopsy assay, the Idylla ctKRAS Mutation Assay, which was developed in partnership with Merck...
List view / Grid view
News
Deloitte and VTC Group form new healthcare technology partnership
13 December 2016 | By Niamh Louise Marriott, Digital Editor
The VTC Group is pleased to announce a partnership with Deloitte, to create a Deloitte Healthcare Virtual Technology Cluster...
EMA to review Sanofi and Regeneron’s dermatitis drug application
13 December 2016 | By Niamh Louise Marriott, Digital Editor
The European Medicines Agency (EMA) has accepted for review the marketing authorisation application for Sanofi and Regeneron’s Dupixent (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.
Success for EIP Pharma’s two Phase 2a Alzheimer’s Disease clinical trials
13 December 2016 | By Niamh Louise Marriott, Digital Editor
The results of two recently completed Phase 2a clinical trials that demonstrated significant Alzheimer's disease relevant pharmacological activity...
Novartis’ SMS for Life 2.0 to improve access to medicines in Nigeria
12 December 2016 | By Niamh Louise Marriott, Digital Editor
The new and enhanced SMS for Life 2.0 program will now use smartphone and tablet computers to address key operational challenges at peripheral healthcare...
Novartis’ NSCLC study shows 16.6 month progression-free survival
12 December 2016 | By Niamh Louise Marriott, Digital Editor
Patients with ALK+ advanced non-small cell lung cancer treated with Zykadia had a median progression-free survival of 16.6 months, compared to placebo...
FDA approves drug that reduces risk of cardiovascular death in diabetics
12 December 2016 | By Niamh Louise Marriott, Digital Editor
It significantly reduced the risk of (the combined primary endpoint) cardiovascular death, non-fatal heart attack or non-fatal stroke by 14% versus placebo...
Canada first to receive new liver cancer treatment option
12 December 2016 | By Niamh Louise Marriott, Digital Editor
The visibility of DC Bead Lumi helps optimise patient treatment by enabling real-time confirmation of bead location during the embolization procedure...
Pfizer fined £85 million for 2600% drug price increase to NHS
9 December 2016 | By Niamh Louise Marriott, Digital Editor
Pharma Giant Pfizer has been fined a record £84.2 million after it broke competition law by charging excessive and unfair prices to the UK...
Dolomite Bio’s Single Cell RNA-Seq System accelerating cancer research
8 December 2016 | By Dolomite Bio
Researchers at The Institute of Cancer Research (ICR), London, are taking advantage of the single cell encapsulation capabilities of Dolomite Bio’s Single Cell RNA-Seq System to investigate resistance mechanisms in prostate cancer...
Almac Group announces strategic partnership with inVentiv Health
7 December 2016 | By Almac Group
Offers clients advanced, best-in-class eClinical technology solutions...
Glass Solutions delivers high quality glassware for laboratory applications
6 December 2016 | By Glass Solutions
Glass Solutions is the supplier of choice for a wide variety of laboratories, providing specialist scientific glassware backed by unrivaled service and support...
Sophia Genetics’ new space-saving and privacy-preserving technology for genomic big data
6 December 2016 | By Niamh Louise Marriott, Digital Editor
The new technology makes sure the privacy of genomic information is not compromised as patients’ data go through various processing steps...
NovoSeven resolved 96.5% of bleeds in haemophilia A or B sufferers
6 December 2016 | By Niamh Louise Marriott, Digital Editor
NovoSeven, a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of bleeds demonstrating efficacy with haemophilia...
Novartis’ Phase II antibody trial reduces frequency of sickle cell pain crises
6 December 2016 | By Niamh Louise Marriott, Digital Editor
Results from the Phase II study show that SEG101 an anti-P-selectin antibody, reduced the median annual rate of sickle cell-related pain crises by 45.3%...
